The MultiPath technology outperforms current culture-based methods by providing pathogen identification results in 30 minutes and antimicrobial susceptibility test results in 4 hours…directly from patient sample.
The MultiPath analyzer is a fully automated “sample-to-answer” platform. By combining this level of automation with rapid tests, we can perform up to 40 antimicrobial susceptibility tests or 200 identification tests in a single 8-hour shift.
The MultiPath platform is unique in its ability to rapidly identify a broad range of pathogens, detect toxins and biomarkers with high sensitivity, and perform rapid phenotypic antimicrobial susceptibility testing.
New videos include 1-1 clinician interviews and detailed product tour Chelmsford, MA – (July 10th, 2019) First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the introduction of new multimedia content on the homepage of the First Light Diagnostics website. The new content…
Additional funds to support the company’s diagnostic platform initiatives Chelmsford, MA – (June 19, 2019) – First Light Diagnostics, Inc., a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis and treatment of life-threatening, antibiotic-resistant infections, today announced the closing of a $4.5 million debt financing. This includes a Lease Line with CSC…
CHELMSFORD, Mass., June 6, 2019 (Newswire.com) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced its participation at the American Society for Microbiology’s ASM Microbe 2019 Event in San Francisco, California, from June 20-24. First Light Diagnostics will be exhibiting in the Innovation Zone, the newest addition…
